vida: extract claims from 2026-05-05-pmc12694361-glp1-appetite-eating-disorders-systematic-review

- Source: inbox/queue/2026-05-05-pmc12694361-glp1-appetite-eating-disorders-systematic-review.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: structural
 sourcer: MDPI Nutrients
 supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
-related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
 ---
 
 # No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
@@ -24,3 +24,10 @@ This review explicitly confirms that evidence for GLP-1 receptor agonists in ano
 **Source:** PMC/Journal of Clinical Medicine systematic review, 2025
 
 Review confirms 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders, while simultaneously documenting case evidence and calling for longer-term follow-up studies (up to 5 years) to detect delayed ED symptom onset.
+
+
+## Supporting Evidence
+
+**Source:** PMC12694361 systematic review
+
+Systematic review (October 2025, MDPI Nutrients) provides strongest current evidence synthesis: 'To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN.' Evidence quality characterized as 'low-to-moderate confidence throughout' with restrictive ED evidence 'scarce and inconclusive.' Most studies are 'short-term, narrowly sampled, and methodologically limited.'

domains/health/glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap.md

@@ -17,3 +17,10 @@ related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-po
 # Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
 
 Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed' supporting direct causality, while Dr. Anjali Pandit states 'not seeing this frequently' suggesting prescriber screening matters significantly. This is not a scientific debate about interpretation of shared data — it's a pre-data debate where different clinical populations and practices produce different observed patterns. Keshen's observation supports pharmacological causation; Pandit's suggests population selection (careful screening prevents cases). The divergence itself is evidence of the current state: we are in the clinical pattern recognition phase before systematic epidemiological data. NBC News notes 'no drug label warnings about ED risk currently exist' and the Collaborative of Eating Disorders Organizations is 'calling for mandatory screening before prescribing' — regulatory and professional responses to uncertainty rather than established risk. This represents the characteristic evidence gap where case reports accumulate but incidence rates, risk factors, and causal pathways remain unquantified.
+
+
+## Supporting Evidence
+
+**Source:** PMC12694361 systematic review
+
+Systematic review characterizes current evidence state as 'low-to-moderate confidence throughout' with BED/BN findings 'preliminary' and restrictive ED evidence 'scarce and inconclusive.' Explicitly identifies methodological limitations: 'most studies are short-term, narrowly sampled, and methodologically limited.' Long-term follow-up data (>1 year) identified as missing.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -38,3 +38,10 @@ ANAD's epistemic honesty is striking: 'We simply do not know if these medication
 **Source:** NBC News 2024-08-15
 
 Collaborative of Eating Disorders Organizations calling for mandatory screening before prescribing, indicating current practice lacks standardized pre-treatment ED assessment. No drug label warnings about ED risk exist as of August 2024 despite accumulating case reports.
+
+
+## Extending Evidence
+
+**Source:** PMC12694361 systematic review
+
+Review frames GLP-1RAs as 'at the intersection of medical innovation and psychological risk' requiring 'integrated psychological monitoring within multidisciplinary care.' This operationalizes the structural capacity requirement through specific screening infrastructure rather than individual clinician knowledge.

domains/health/glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Systematic review establishes multi-component screening infrastructure as clinical governance recommendation for GLP-1 prescribing
+confidence: experimental
+source: PMC12694361 systematic review, MDPI Nutrients 2025
+created: 2026-05-05
+title: GLP-1 eating disorder screening protocol combining SCOFF questionnaire, recent ED history review, and compensatory behavior assessment is recommended for pre-treatment risk stratification
+agent: vida
+sourced_from: health/2026-05-05-pmc12694361-glp1-appetite-eating-disorders-systematic-review.md
+scope: functional
+sourcer: PMC12694361
+supports: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+---
+
+# GLP-1 eating disorder screening protocol combining SCOFF questionnaire, recent ED history review, and compensatory behavior assessment is recommended for pre-treatment risk stratification
+
+The systematic review identifies a specific pre-treatment screening protocol for GLP-1 receptor agonist prescribing: (1) SCOFF questionnaire administration, (2) recent ED history review, (3) assessment for compensatory behaviors, and (4) weight-suppression history evaluation. This represents a clinical governance recommendation addressing the 92 percent dietitian support gap documented in existing claims. The review also establishes red flags during treatment: rapid weight loss, dizziness/syncope, escalating restriction, and purging or laxative use. This screening infrastructure addresses the structural capacity gap identified in glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge. The protocol is positioned as 'recommended' not 'required,' reflecting the absence of regulatory mandate despite clinical consensus. This creates a parallel to the ambient-ai-scribes-create-three-party-liability-exposure-outside-fda-oversight pattern where clinical best practice outpaces regulatory infrastructure.

domains/health/glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway.md

@@ -23,3 +23,10 @@ ANAD documents that GLP-1 receptor agonists' most common side effects—nausea,
 **Source:** ANAD 2026 clinical guidance
 
 ANAD states: 'Delayed gastric emptying can trigger or worsen purging behaviors, especially in those already vulnerable. Vomiting is always dangerous and risks dehydration and electrolyte imbalance.' This confirms the pharmacological mechanism operates through existing vulnerability, not de novo ED creation.
+
+
+## Extending Evidence
+
+**Source:** PMC12694361 systematic review
+
+Systematic review refines mechanism: 'Gastrointestinal symptoms such as nausea and vomiting may complicate treatment, particularly in patients with purging behaviours, where these side effects could inadvertently reinforce or exacerbate existing cycles' — critically qualifies as 'existing cycles' not de novo induction. Requires pre-existing behavioral vulnerability markers: high perfectionism, obsessive-compulsive traits, elevated baseline emotional eating, mixed binge-purge patterns, weight suppression history.

domains/health/glp1-induced-gi-side-effects-reinforce-existing-purging-cycles-but-no-clinical-evidence-supports-de-novo-eating-disorder-induction.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: Systematic review finds GI symptoms complicate existing purging behaviors but closes the de novo causation hypothesis for anorexia nervosa
+confidence: experimental
+source: PMC12694361 systematic review, MDPI Nutrients 2025
+created: 2026-05-05
+title: GLP-1-induced GI side effects may reinforce pre-existing purging cycles but no clinical evidence supports de novo eating disorder induction in patients without behavioral vulnerability
+agent: vida
+sourced_from: health/2026-05-05-pmc12694361-glp1-appetite-eating-disorders-systematic-review.md
+scope: causal
+sourcer: PMC12694361
+supports: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
+challenges: ["glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway"]
+related: ["glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1-induced GI side effects may reinforce pre-existing purging cycles but no clinical evidence supports de novo eating disorder induction in patients without behavioral vulnerability
+
+This systematic review provides the strongest current evidence synthesis on GLP-1 receptor agonists and eating disorder risk. The review explicitly states: 'To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN.' This is a definitive closure of the de novo causation hypothesis for anorexia nervosa. The review identifies that 'gastrointestinal symptoms such as nausea and vomiting may complicate treatment, particularly in patients with purging behaviours, where these side effects could inadvertently reinforce or exacerbate existing cycles' — critically, the qualifier is 'existing cycles,' not new onset. The mechanism requires pre-existing behavioral vulnerability: vulnerability markers include high perfectionism, obsessive-compulsive traits, elevated baseline emotional eating, mixed binge-purge patterns, and weight suppression history. The review characterizes evidence quality as 'low-to-moderate confidence throughout' with BED/BN findings 'preliminary' and restrictive ED evidence 'scarce and inconclusive.' This closes the GI-mediated purging disconfirmation hypothesis from session 36 — the pharmacological pathway requires behavioral substrate.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -45,3 +45,10 @@ ANAD (the authoritative US professional society for eating disorders) formalizes
 **Source:** Northwestern Medicine JCI 2025
 
 The AgRP silencing mechanism strengthens the case for mandatory (not just recommended) pre-treatment screening. If semaglutide pharmacologically removes the biological safeguard against starvation, prescribing without ED screening is analogous to removing a safety system without checking if backup protections exist. The mechanism suggests screening should specifically assess for restrictive eating patterns, not just diagnosed eating disorders.
+
+
+## Extending Evidence
+
+**Source:** PMC12694361 systematic review
+
+Systematic review establishes specific screening protocol components: SCOFF questionnaire administration, recent ED history review, assessment for compensatory behaviors, weight-suppression history evaluation. Also identifies treatment red flags: rapid weight loss, dizziness/syncope, escalating restriction, purging or laxative use. Positioned as clinical governance recommendation within 'multidisciplinary care' framework.

inbox/archive/health/2026-05-05-pmc12694361-glp1-appetite-eating-disorders-systematic-review.md

@@ -7,10 +7,13 @@ date: 2025-10-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, systematic-review, binge-eating, bulimia, anorexia, screening, behavioral-health, co-treatment]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content